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ABSTRACT
Breast cancer stem cells (BCSCs) play crucial roles in tumor initiation, metastasis 
and therapeutic resistance. A strict dependency between BCSCs and stromal cell 
components of tumor microenvironment exists. Thus, novel therapeutic strategies 
aimed to target the crosstalk between activated microenvironment and BCSCs have 
the potential to improve clinical outcome. Here, we investigated how leptin, as a 
mediator of tumor-stromal interactions, may affect BCSC activity using patient-
derived samples (n = 16) and breast cancer cell lines, and determined the potential 
benefit of targeting leptin signaling in these model systems. Conditioned media (CM) 
from cancer-associated fibroblasts and breast adipocytes significantly increased 
mammosphere formation in breast cancer cells and depletion of leptin from CM 
completely abrogated this effect. Mammosphere cultures exhibited increased leptin 
receptor (OBR) expression and leptin exposure enhanced mammosphere formation. 
Microarray analyses revealed a similar expression profile of genes involved in stem 
cell biology among mammospheres treated with CM and leptin. Interestingly, leptin 
increased mammosphere formation in metastatic breast cancers and expression of 
OBR as well as HSP90, a target of leptin signaling, were directly correlated with 
mammosphere formation in metastatic samples (r = 0.68/p = 0.05; r = 0.71/p = 
0.036, respectively). Kaplan–Meier survival curves indicated that OBR and HSP90 
expression were associated with reduced overall survival in breast cancer patients 
(HR = 1.9/p = 0.022; HR = 2.2/p = 0.00017, respectively). Furthermore, blocking 
leptin signaling by using a full leptin receptor antagonist significantly reduced 
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mammosphere formation in breast cancer cell lines and patient-derived samples. 
Our results suggest that leptin/leptin receptor signaling may represent a potential 
therapeutic target that can block the stromal-tumor interactions driving BCSC-
mediated disease progression.
INTRODUCTION
Carcinoma of the breast is the most common 
malignancy and the leading cause of cancer-related 
death in women worldwide [1]. Despite improvements in 
diagnosis and treatment, metastatic or recurrent disease 
and resistance to therapy remain the principal causes of 
death for breast cancer patients.
In the last years, multiple reports have shown that 
a subpopulation of cancer cells displaying stem cell 
properties and named as cancer stem cells (CSCs) plays 
a crucial role in sustaining tumor growth and progression. 
These cells are characterized by their ability to undergo 
self-renewal, a process that drives tumorigenesis, and 
to differentiate into the non-self-renewing cells forming 
the tumor bulk [2, 3]. From a clinical point of view, the 
main concern with CSCs is related to their resistance to 
conventional treatments (e.g. endocrine-, chemo- and 
radio-therapy), a feature that might be the underlying 
cause of tumor recurrence and metastases [4–6]. Similar 
to embryonic and somatic stem cells, the self-renewal 
and differentiation of CSCs are regulated by both 
intrinsic and extrinsic pathways whose dysregulation 
may be a key event initiating carcinogenesis. Among 
the intrinsic pathways, an important role is displayed by 
developmental signals such as Wnt, Hedgehog, Janus 
kinase 2-signal transducer and activator of transcription 
3 (JAK2-STAT3) and Notch pathways that are frequently 
deranged in cancers [7]. Extrinsic signals that regulate 
stem cell behaviour originate in the surrounding stem 
cell microenvironment, termed as cancer stem niche. 
This niche contains a number of cell types, including 
mesenchymal stem cells (MSCs), cancer-associated 
fibroblasts (CAFs), adipocytes, endothelial and immune 
cells, all of which, through networks of cytokines and 
growth factors, have been shown to influence tumor 
growth and metastasis [8]. Thus, strategies aimed to 
specifically target the interaction between CSCs and their 
microenvironment may represent an important approach to 
improve patient outcome.
Adipocytes and CAFs are the major components 
in breast cancer microenvironment, and along with their 
secreted factors represent key players in stroma-epithelial 
cell interactions. As an important paracrine mediator, the 
adipocyte-derived cytokine leptin, that we have recently 
demonstrated to be also secreted by CAFs [9], has been 
correlated with breast cancer occurrence. Leptin exerts its 
biologic function through binding to its receptor (OBR) 
which activates multiple downstream signaling pathways 
such as those involving JAK2-STAT3, mitogen-activated 
protein kinase (MAPK), and phosphatidylinositol 3-kinase/
protein kinase B (PI3K/AKT) [10]. Leptin and both short 
and long OBR isoforms are overexpressed in breast cancer, 
especially in higher grade tumors and are associated 
with distant metastases [11, 12]. It has been extensively 
demonstrated that this cytokine, acting in an autocrine, 
endocrine and paracrine manner, may modulate many 
aspects of breast tumorigenesis from initiation and primary 
tumor growth to metastatic progression [13–15]. Besides, 
crosstalk with other different signaling molecules such 
as estrogens, growth factors and inflammatory cytokines 
further increases leptin impact on breast tumor progression 
[16–21]. Moreover, leptin is able to shape the tumor 
microenvironment within the mammary gland by inducing 
multiple concurrent events such as migration of endothelial 
cells, angiogenesis and recruitment of macrophages and 
monocytes [13–15, 22]. Interestingly, recent studies have 
also reported that leptin signaling may be involved in the 
promotion of CSC phenotype [23–25] and that inhibition of 
STAT3 suppresses leptin-induced CSC activity and cancer 
progression in diet-induced obese rats [26].
The aim of the current study was to evaluate the role 
of leptin, as a mediator of the tumor-stroma interaction, 
in regulating breast CSC activity using breast cancer cell 
lines and patient-derived breast cancer cells isolated from 
metastatic ascites and pleural effusions. Particularly, we 
investigated: i) the impact of CAFs and adipocytes isolated 
from stromal breast tissues on mammosphere formation 
and self-renewal in breast cancer cells; ii) the specific 
role of leptin and its receptor in influencing breast CSC 
phenotype in the context of the tumor microenvironment; 
iii) the effect of inhibiting leptin signaling as potential 
therapeutic target to reduce breast CSC activity in in vitro 
and ex vivo models.
RESULTS
CAFs and adipocytes induce mammosphere 
formation in breast cancer cells through leptin 
secretion
To assess the ability of stromal cells to affect CSC 
activity in breast cancer cells we performed co-culture 
experiments. As experimental models for breast CSCs 
(BCSCs), we used estrogen receptor (ER)-α-positive 
MCF-7 cells grown as mammospheres. This culture 
system has been used to characterize, enrich and propagate 
breast cancer cells with stem-like phenotype, relying on 
the feature of stem cells to escape anoikis and grow as 
spheroids in anchorage-independent conditions [27]. 
MCF-7 mammosphere cells were characterized by flow 
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cytometric analysis that revealed an enrichment of CD44+/
CD24− subpopulation compared to MCF-7 monolayer 
cells (Supplementary Figure S1A). In addition, real-time 
PCR further revealed that genes associated with stem 
cell phenotype, including OCT4, N-CAD, BMI1, SOX4, 
were expressed in mammosphere cells at higher levels 
than in monolayer cells (Supplementary Figure S1B). 
Moreover, MCF-7 mammosphere cells were also analyzed 
for the expression of ERα (Supplementary Figure S1C 
and 1D). As stromal cells, we used either CAFs isolated 
from biopsies of primary breast tumors or human breast 
adipocytes obtained after preadipocyte differentiation. 
CAFs possessed the basic fibroblast characteristics 
with long and spindle-shaped morphology and highly 
expressed alpha-smooth muscle actin (α-SMA), vimentin, 
and fibroblast activation protein (FAP) (Supplementary 
Figure 2A and 2B). Adipocytes displayed a classical 
morphological phenotype characterized by accumulation 
of lipid droplets associated with the expression of specific 
markers as PPARγ and leptin (OB) (Supplementary 
Figure S2C). Using co-culture experiments, we examined 
mammosphere formation from MCF-7 cells in the 
presence or absence of conditioned media (CM) harvested 
from CAFs and adipocytes. Compared to the cells 
cultured alone, MCF-7 cells co-cultured with CAF- or 
adipocyte-derived CM showed a significant enhancement 
in mammosphere forming efficiency (MFE) (Figure 1A). 
Stem cells are maintained in the primary mammospheres 
through self-renewal, and are able to give rise to secondary 
mammospheres when cells from the primary spheres are 
dissociated and allowed to grow in anchorage-independent 
conditions. Therefore, we carried out secondary 
mammosphere cultures to examine the effects of CM 
on BCSC self-renewal. Our experiments demonstrated 
an increased self-renewal in MCF-7 cells treated with 
CAF- and adipocyte-derived CM in the first generation 
compared with the untreated spheres (Figure 1B and 1C). 
These data suggest that BCSC activity is influenced by 
Figure 1: Leptin mediates the effects of stromal cell-CM on breast cancer cell mammosphere formation. Mammosphere 
Forming Efficiency (MFE) evaluated in MCF-7-M1 (A) and MCF-7-M2 (B) in the presence or absence (−) of CAF- and Adipocyte-derived 
Conditioned Media (CAF-CM and Adipo-CM, respectively). MFE was calculated by dividing the number of mammospheres (colonies > 
50 μm) formed by the number of the cells plated and expressed as fold change compared to untreated cells (−). (C) Representative phase-
contrast images of mammospheres treated as in panel (B) are shown. MFE evaluated in MCF-7-M1 (D) and MCF-7-M2 (E) in the presence 
or absence (−) of leptin-immunodepleted CAF-CM and Adipo-CM (-Lep). IgG: CM immunodepleted with nonspecific antibody. The 
values represent the means ± s.d. of three different experiments each performed in triplicate. *p < 0.05.
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soluble factors secreted from stromal cells. Thus, given 
the role of leptin as an important cytokine secreted by both 
CAFs and adipocytes, we assessed the impact of leptin 
in the context of the heterotypic signaling working in 
BCSC–stromal interactions. First, ELISA measurement in 
CM from stromal cells showed that leptin levels were 2,4 
± 0,12 ng/mg protein and 20,32 ± 2 ng/mg protein in CAF- 
and adipocyte-derived CM, respectively. Leptin was then 
immunodepleted from CAF- and adipocyte-derived CM 
using a specific leptin antibody, and resulting media were 
tested for the ability to induce mammosphere formation in 
breast cancer cells. AS shown in Figure 1D and 1E, leptin 
depletion significantly decreased the MFE/self-renewal 
promoted by stromal cell-derived CM.
Targeting leptin signaling reduces stem cell 
activity mediated by stromal cells
Our previous experiments indicate that leptin may 
represent an important paracrine molecule that mediates 
the interaction between stromal cells and BCSCs. To 
support this observation, we tested the effect of a full leptin 
receptor antagonist, peptide LDFI, on BCSC activity. We 
have previously shown that this peptide inhibits leptin-
induced breast cancer growth in vitro and exhibits anti-
neoplastic activities in vivo [28]. Our data demonstrated 
that treatment with peptide LDFI significantly reduced 
MFE/self-renewal promoted by stromal cell-derived CM 
in MCF-7 cells (Figure 2A). To extend the results obtained, 
we have grown the ERα-negative MDA-MB-231 breast 
cancer cells as mammospheres and evaluated the effects 
of CAF- or adipocyte-CM in the presence or absence of 
peptide LDFI. Treatment of MDA-MB-231 mammosphere 
cultures with CAF- or adipocyte-derived CM significantly 
increased MFE/self-renewal and the addition of the OBR 
antagonist LDFI strongly reduced these effects (Figure 
2B), confirming that leptin/leptin receptor may play a 
crucial role in maintaining the BCSC traits mediated by 
stromal cells in different cellular backgrounds.
Leptin signaling regulates mammosphere 
formation/self-renewal activity of breast cancer 
cells
Having shown that stromal cells regulate BCSC 
activity through secretion of leptin, we next investigated 
Figure 2: Effects of a selective leptin receptor antagonist on breast cancer stem cell activity. MFE evaluated in MCF-7-M1 
and MCF-7-M2 (A) and in MDA-MB-231-M1 and MDA-MB-231-M2 (B) treated with CAF-CM and Adipo-CM with/without peptide 
LDFI (1 μg/ml). The values represent the means ± s.d. of three different experiments each performed in triplicate. *p < 0.05.
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the direct involvement of this cytokine in the regulation 
of mammosphere formation/self-renewal in MCF-7 
cells. In agreement with previous data demonstrating 
that leptin receptor plays a crucial role in maintaining 
cancers in a stem cell-like state [23–26], we found that 
MCF-7 mammosphere cultures exhibited increased 
OBR mRNA expression and in a greater extent the long 
isoform, compared to monolayer cells (Figure 3A). 
Accordingly, leptin treatment of mammosphere cultures 
resulted in a significant increase in MFE/self-renewal and 
in an enhanced percentage of CD44+/CD24− population 
compared with untreated cells (Figure 3B, 3C and 3D). 
Accordingly, in MDA-MB-231 mammosphere cultures, 
we observed a significant increase in the long isoform 
of OBR mRNA expression compared to monolayer cells, 
and an enhanced MFE/self-renewal after leptin exposure 
(Supplementary Figure S3), demonstrating that this 
cytokine can directly regulate BCSC activity.
Since BCSCs display increased cell motility and 
invasion, we tested the effects of leptin on the migratory 
potential of MCF-7 mammospheres. Our data clearly showed 
that leptin exposure increased the number of migrated cells 
suggesting that this cytokine can facilitate the invasive 
behavior of BCSCs (Figure 3E). Next, OBR expression 
was stably knocked-down using lentiviral delivered short 
hairpin RNA (OBR sh) in MCF-7 cells (Figure 3F, left 
panel). Suppression of OBR expression led to a significant 
inhibition of MFE (Figure 3F, right panel), implying that this 
gene is necessary for maintaining cancer stem-like properties 
in breast cancer cells. In addition, we observed that leptin 
treatment induced the phosphorylation of specific OBR 
downstream signaling molecules such as STAT3, Akt and 
p42/44 MAPK (Figure 3G). As expected, the increase in 
MFE induced by leptin was reversed by the JAK2-STAT3 
inhibitor AG490, the MEK1 inhibitor PD98059 and the 
PI3K/AKT inhibitor LY294002 (Figure 3H), suggesting 
Figure 3: Leptin induces MFE in breast cancer cells. A. Leptin receptor long (OBRL) and short (OBRS) isoform mRNA levels, 
evaluated by real time RT-PCR, in MCF-7, MCF-7-M1 and MCF-7-M2 cells. Each sample was normalized to its GAPDH mRNA content. 
B. MFE in MCF-7-M1 and MCF-7-M2 in the presence or absence (−) of leptin 500 ng/ml (Lep). C. Representative phase-contrast 
images of mammospheres treated as in panel (B) are shown. D. CD44+/CD24− population in MCF-7-M2 cells treated or not (−) with Lep. 
E. Transmigration assays in MCF-7-M1 and MCF-7-M2-derived cells treated or not (−) with Lep. F. MCF-7 cells were stably transfected 
with either a scrambled shRNA (control-sh) or OBR shRNA (OBR-sh). OBRL mRNA content was evaluated by real time RT-PCR  
(left panel). Each sample was normalized to its GAPDH mRNA content. MFE in MCF-7-M1 derived from either control-sh or OBR-sh 
clones (right panel). G. Immunoblotting of phosphorylated (p), STAT3 (Tyr705), Akt (Ser473), and MAPK (Thr202/Tyr204) at the indicated 
residues measured in cellular extracts from MCF-7-M1 cells treated or not (−) with Lep. GAPDH, loading control. H. MFE in MCF-7-M1 
treated with Lep and AG490 (AG-20 μmol/L), PD98059 (PD-10 μmol/L) or LY294002 (LY-10 μmol/L). The values represent the means ± 
s.d. of three different experiments each performed in triplicate. *p < 0.05.
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that leptin promotes stem cell properties via activation of 
classical leptin signaling pathways. In agreement with 
these observations, we also found an up-regulation of 
well-known leptin target genes as OBR and the heat shock 
protein 90 (HSP90) [20] in MCF-7 cells treated with leptin 
(Supplementary Figure S4A and 4B)
Gene expression profiling in leptin or stromal 
CM-treated mammosphere-derived cells
To determine whether leptin, CAF- and adipocyte-
CM may similarly affect gene expression profile in 
mammosphere-derived cells, we performed gene 
expression profiling analysis on total RNA extracted 
from the second generation spheres. Microarray results 
highlighted several RNAs differentially expressed in 
treated vs untreated MCF-7 mammospheres. Venn diagram 
analysis was used to compare the gene lists and to identify 
those genes that are unique and in common among the 
three treatments (Figure 4A). A total of 2270 transcripts 
were commonly regulated in all treated samples (808 
up- and 1462 down-regulated transcripts, respectively). 
It should be noted that the global overlap among genes 
expressed in treated samples includes a number of genes 
known to play a role in stem cell biology such as BMI1, 
SUZ12, YES1, SOX4 (Figure 4B, left panel, Supplementary 
Table S2). Similar trends were also observed for the 
expression of other genes involved in cell cycle control 
(Figure 4B, middle panel, Supplementary Table S3). 
Moreover, treated samples displayed up-regulation 
of some transcripts related to the heat shock protein 
family, that recently have been suggested to be crucial 
in sustaining proliferation and self-renewal of stem cells 
[29] (Figure 4B, right panel, Supplementary Table S4). 
To validate our microarray study MCF-7 mammospheres 
treated with leptin were evaluated for the expression of a 
Figure 4: Gene expression profiling in mammosphere cultures treated with stromal cell-CM or leptin. A. Venn diagram 
of up-(left panel) and down-(right panel) regulated transcript identified by microarray analysis in MCF-7-M2 cells treated with CAF-CM, 
Adipo-CM or Lep compared to untreated samples. B. Heat-maps of stemness related-genes, cell cycle related-genes and HSP family genes 
from microarray data. Gene expression changes were calculated in treated cells with respect to the untreated controls. Transcript showing a 
DiffScore ≤ − 30 and ≥ 30, corresponding to a p-value of 0.001, and significant fold change in treated vs untreated ≥ 1.5 were considered. 
C. Real-time RT-PCR validation of a subset of genes in MCF-7-M2 cells treated or not (−) with Lep. Each sample was normalized to its 
GAPDH mRNA content. The values represent the means ± s.d. of three different experiments each performed in triplicate. *p < 0.05 vs 
untreated (−) sample.
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panel of genes by using real-time PCR (Figure 4C). Taken 
together, gene expression profile analyses strongly support 
the role of leptin as a crucial paracrine molecule able to 
mediate the microenvironment effects on BCSC activity.
Leptin increases patient-derived mammosphere 
formation/self-renewal activity
The role of leptin in the regulation of BCSC 
activity was then evaluated by using patient-derived 
breast cancer cells isolated from metastatic ascites or 
pleural effusions. Tumor histology, grade, hormone 
receptors and HER2 status of the primary tumors were 
reported in Table 1. Mammosphere cultures treated with 
leptin resulted in a significant increase in MFE compared 
to untreated samples (n = 10, Figure 5A). Secondary 
mammosphere formation was observed only in four 
samples and treatment with leptin significantly increased 
self-renewal in three of them (Figure 5B). Besides, four 
human metastatic samples taken from patients with 
breast cancer were also treated with peptide LDFI. MFE 
induced by leptin was significantly decreased with the 
addition of LDFI (Figure 5C). Interestingly, treatment 
with peptide LDFI alone reduced the mammosphere 
formation, underlying how this peptide negatively 
interferes with leptin autocrine loop (Figure 5C). 
Then, to investigate the direct involvement of OBR 
in the regulation of mammosphere formation, OBR 
gene expression was analyzed in cells from metastatic 
ascites and pleural effusion fluids using microarray data. 
There was a significant direct correlation between the 
expression of OBR mRNA in cells from the metastatic 
fluids and MFE (r = 0.68; p = 0.05, Figure 5D). In 
agreement with the microarray data obtained in MCF-
7 mammospheres, a significant correlation between 
MFE and HSP90 gene expression in the same metastatic 
patient-derived samples (r = 0.71; p = 0.036) was also 
observed (Figure 5E). These data suggest that patients 
with higher levels of OBR and HSP90 mRNAs in cells of 
metastatic fluids have greater ex vivo CSC activity.
OBR expression correlates with reduced overall 
survival in breast carcinomas
To investigate the clinical significance of OBR gene 
expression in human breast cancers the relationship between 
OBR levels and overall survival (OS) of breast cancer 
patients (n = 781) was estimated by Kaplan–Meier analysis. 
Survival curves indicated that women with high OBR 
expression exhibited a lower rate of OS than those with 
low OBR expression (HR = 1.9, p = 0.022) (Figure 6A). 
Similarly, breast carcinoma patients with high HSP90 
Table 1: Summary of metastatic patients-derived cancers
SAMPLE ID AGE SOURCE Histology GRADE ER PR HER2
BB3RC29 70 ASC UN UN POS POS NEG
BB3RC46 68 ASC ILC 2 POS POS NEG
BB3RC50 46 ASC IDC 2 POS POS NEG
BB3RC591 69 ASC ILC 2 POS POS NEG
BB3RC60 66 ASC ILC 2 POS POS NEG
BB3RC652 62 ASC ILC 2 POS POS NEG
BB3RC661 69 ASC ILC 2 POS POS NEG
BB3RC702 62 ASC ILC 2 POS POS NEG
BB3RC71 48 PE UN 3 POS POS POS
BB3RC79 UN PE IDC 3 NEG NEG NEG
BB3RC81 55 ASC IDC 2 POS POS NEG
BB3RC84 UN PE UN 3 NEG NEG NEG
BB3RC90 66 PE IDC/ILC 2 P0S POS NEG
BB3RC92 61 ASC IDC 1 POS POS NEG
BB3RC93 UN ASC UN UN POS POS NEG
BB3RC94 41 ASC UN UN POS POS NEG
1, 2These samples were obtained at different time points from the same patients
Sixteen patient-derived breast cancer samples were used in this study. Tumor histology and grade for metastatic samples 
(ASC and PE) relates to the primary cancer. Abbreviation: UN unknown, PE pleural effusion, ASC ascites sample, ILC 
invasive lobular carcinoma , IDC invasive ductal carcinoma, POS positive, NEG negative, ER Estrogen Receptor, PR 
Progesterone Receptor, HER2, epidermal growth factor receptor 2.
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expression had decreased OS compared with those with low 
HSP90 expression (HR = 2.2, p = 0.00017) (Figure 6B).
Basal-like breast cancer is an aggressive tumor 
subtype, composed by primitive undifferentiated cells. 
Indeed, basal-like breast tumors, which are enriched for 
CD44+/CD24− cells, exhibit epithelial–mesenchymal 
transition features and express high levels of stem cell-
regulatory genes [30–34]. In agreement with these 
observations, the results of the Kaplan-Meier analysis 
indicated a more relevant discrimination in terms of 
overall survival between high and low expression of OBR 
and HSP90 in basal breast cancer patients (n = 143) (HR = 
4.4, p = 0.011; HR = 5.2, p = 0.013 respectively) (Figure 
6C and 6D).
DISCUSSION
The heterotypic signals arising in the tumor-
associated stroma have been shown to be important in 
inducing and maintaining a stem-like state in the tumor 
cells through either the secretion of soluble molecules or 
cell–cell communication [35, 36]. Particularly, in the case 
of breast carcinoma, it has been reported that various types 
of stromal cells via growth factors and cytokines may 
enhance the proliferation and survival of BCSCs, induce 
angiogenesis, and recruit tumor-associated macrophages 
and other immune cells, which in turn secrete additional 
factors promoting tumor cell invasion and metastasis [8].
Here we demonstrated, for the first time, that leptin 
and its receptor play a crucial role in mediating the 
interaction between stromal cells (CAFs and adipocytes) 
and BCSCs. The initial conditioned media experiments 
indicated that the entire complement of secretory proteins 
released by CAFs and adipocytes significantly increase 
MFE/self-renewal in breast cancer cells. An important 
role is played by leptin as a fundamental environmental 
regulator of CSCs in the cancer stem niche. Indeed, 
either leptin immunodepletion from CAF- and adipocyte-
derived CM or inhibition of leptin signaling by using 
peptide LDFI, a small-molecule that acts as a full leptin 
Figure 5: Leptin enhances mammospheres formation/self-renewal activity in patient-derived metastatic cells. 10 metastatic 
fluid samples obtained from breast cancer patients (BB3RC59/BB3RC66/BB3RC71–94) undergoing palliative drainage of symptomatic 
ascites or pleural effusions were used (Table 1). MFE in metastatic patient-derived cells grown as primary (Metastatic samples M1) (A) or 
secondary (Metastatic samples M2) (B) mammospheres in the presence or absence (−) of Lep. (C) MFE in 4 Metastatic sample M1 untreated 
(−) or treated with Lep, peptide LDFI (1 μg/ml), and Lep+LDFI. The values represent the means ± s.d. of three different experiments each 
performed in triplicate. *p < 0.05. n.s.:nonsignificant. Correlation between OBR (D) or HSP90 mRNA expression (E) in cells of the metastatic 
fluids and MFE (8 patients/BB3RC29–70) (Pearson correlation coefficient, r = 0.68, p = 0.05; r = 0.71, p = 0.036, respectively).
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receptor antagonist [28], reduced the effects of CM on 
mammosphere formation. Gene expression profiling 
revealed a significant overlap of regulated genes in 
mammosphere cells following treatment with CAF-, 
adipocyte-derived CM or leptin. Of particular interest 
was the observation that genes commonly expressed in 
all treated-samples include several of those involved 
in stemness. Among these, the polycomb gene BMI1, 
which has been reported to play an important role in 
self-renewal of stem cells and has a positive correlation 
with clinical grade/stage and poor prognosis [37], was 
one of the most highly induced in all treated cells. One 
of the features of CSCs is the uncontrolled proliferation, 
perhaps due to a reduced responsiveness to negative 
growth regulators or to the loss of contact inhibition 
and gap junction intercellular communication [38]. Our 
results clearly evidenced that a number of genes involved 
in cell cycle control showed a similar expression profile 
upon treatment with stromal-CM and leptin. Another 
family of genes, crucial in sustaining self-renewal of 
stem cells [29], is the heat shock protein family. We 
have previously demonstrated that the HSP90, a main 
functional component of this chaperone complex, is a 
target of leptin in breast cancer cells [20]. Our microarray 
data showed that some transcripts of the HSP family were 
upregulated in stromal-CM and leptin-treated samples. 
Thus, since the expression pattern of genes regulated by 
leptin and involved in stem cell biology closely mirrors 
those modulated by stromal cells, it is reasonable to 
speculate that leptin may represent a critical paracrine 
Figure 6: Correlation between OBR and HSP90 mRNA levels and overall survival in breast cancer. Kaplan–Meier 
survival analysis in breast carcinoma patients (n = 781) with high and low OBR (A) or HSP90 (B) expression analyzed as described in 
Materials and Methods. Kaplan–Meier survival analysis in basal breast cancer patients (n = 143) with high and low OBR (C) or HSP90 
(D) expression. Kaplan-Meier survival graph, and hazard ratio (HR) with 95% confidence intervals and logrank P value.
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molecule in mediating the microenvironment effects on 
BCSC activity.
The expression of the leptin receptor is a 
characteristic feature of CSCs and of a broad array of 
embryonic and induced pluripotent stem cells, which 
exhibit an increased response to leptin including 
phosphorylation and activation of STAT3 and induction 
of stem cell markers, as OCT4 and SOX2 [23]. 
Leptin receptor has also been reported as a marker 
for identification and in vivo fate of bone marrow 
mesenchymal stem cells (MSCs) [39] and leptin signaling 
represents an essential step for the enhanced survival, 
chemotaxis and therapeutic properties of MSCs induced 
by hypoxia [40, 41]. Moreover, it has been reported that 
leptin is able to regulate and activate several signaling 
pathways and oncogenes which are critically implicated 
in BCSCs [42–46] and leptin deficiency in MMTV-Wnt-1 
transgenic mice results in functional depletion of BCSCs 
leading to less tumor outgrowth [24]. More recently, it 
has also been demonstrated that OBR is necessary for 
maintaining a CSC-like state in TNBC cells [25] and high 
OBR expression induced by the adiposity-leptin enriched 
environment generates a population with enhanced CSC 
properties and tumorigenic capacity [26]. Our studies 
extended these previous findings by demonstrating a 
direct involvement of leptin in sustaining breast cancer 
stem cell behavior using both breast cancer cell lines 
and metastatic breast cancer patient-derived cells. We 
found that MCF-7 mammospheres exhibited increased 
OBR mRNA expression, while OBR silencing caused a 
significant reduction in the sphere-forming efficiency. 
Treatment with leptin induced an increase in MFE, self-
renewal and an enhanced percentage of CD44+/CD24− 
cell population, through the activation of the classical 
signaling pathways. Importantly, we also showed that 
leptin is able to increase the mammosphere formation 
and self-renewal activity in metastatic breast cancer cells 
isolated from patients. Moreover, OBR mRNA expression, 
analyzed in cells from metastatic fluids, was directly 
correlated with mammosphere formation activity ex vivo. 
In agreement with our data of gene expression profile, a 
significant positive correlation between MFE and HSP90 
mRNA expression in the same metastatic patient-derived 
samples was observed.
It has been previously reported that high-grade 
tumors associated with poor prognosis display an 
enrichment of BCSCs [47, 48]. Here, using Kaplan-Meier 
analysis we found that OBR expression, which is crucial 
in maintaining stem cell phenotype, was associated with 
reduced overall survival in breast carcinomas suggesting 
its potential role as a prognostic factor. Interestingly, 
in basal-like breast cancer patients, a more relevant 
discrimination in terms of overall survival between high 
and low OBR expression could be observed. Finally, we 
demonstrated that blocking leptin signaling by using 
the peptide LDFI significantly reduced mammosphere 
formation in metastatic breast cancer patient-derived 
cells, suggesting that strategies aimed at inhibiting leptin 
signaling represent a rationale therapeutic approach to 
target cancer stem cells.
In conclusion, our findings identify, for the first 
time, leptin as an important paracrine molecule that 
mediates the interaction between stromal cells and BCSCs, 
providing novel insights into understanding how BCSCs 
are influenced by the tumor microenvironment. As clinical 
implications, these data suggest that targeting leptin/leptin 
receptor signaling generated in the microenvironment 
may be useful for BCSC eradication and eventually to 




Human MCF-7 and MDA-MB-231 breast 
cancer epithelial cells were acquired in 2010 and 2015 
respectively, from American Type Culture Collection 
where they were authenticated, stored according to 
supplier’s instructions, and used within 4 months after 
frozen aliquots recovery. Breast subcutaneous human 
female preadipocytes (Lot.#:BR071812B; BR070810) 
were from Zen-Bio. Adipocytes, obtained following 
differentiation procedure, were routinely maintained 
in Adipocyte maintenance medium (Zen-Bio). Every 4 
months, cells were authenticated by single tandem repeat 
analysis at our Sequencing Core; morphology, doubling 
times, estrogen sensitivity, and mycoplasma negativity 
were tested (MycoAlert, Lonza).
Cancer associated fibroblast (CAF) isolation
Human breast cancer specimens were collected 
in 2013 from primary tumors of patients who signed 
informed consent following the procedures previously 
described [9]. Briefly, small pieces of fresh tumor 
excision were digested (500 IU collagenase in 
Hank’s balanced salt solution; Sigma; 37°C for 2 h). 
After differential centrifugation (90 g for 2 min), the 
supernatant containing CAFs was centrifuged (500 g 
for 8 min), resuspended, and cultured in RPMI-1640 
medium supplemented with 15% FBS and antibiotics. 
The fibroblastic nature of the isolated cells was confirmed 
by microscopic determination of morphology, and 
characterization by αSMA, vimentin, pan-Cytokeratin 
and fibroblast activation protein (FAP) expression. CAFs 
between 4 and 10 passages were used.
Immunofluorescence
Immunofluorescence assay was performed as 
described [9] using anti-α-SMA or ERα antibodies and 
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fluorescein isothiocyanate-conjugated secondary antibody 
(Santa Cruz Biothecnology).
Conditioned medium (CM) and leptin-
immunodepleted CM
CM from CAFs and adipocytes and leptin-
immunodepleted CM were obtained as described [9]. 
Leptin levels were measured by ELISA (LDN).
Metastatic breast cancer patient-derived cells
Pleural effusion and ascites samples were 
obtained from patients with metastatic breast cancer 
undergoing palliative drainage at The Christie Hospital 
NHS Foundation Trust Manchester (UK). Metastatic 
breast sample details in Table 1. Ascites and pleural 
effusions were centrifuged at 1000 g for 10 min at 4°C 
and suspended in PBS. Erythrocytes and leucocytes were 
removed by centrifugation through Lymphoprep solution 
(Axis Shield), followed by removal of CD45-positive cells 
using anti-CD45 magnetic beads (Miltenyi Biotec). Single 
cell suspension of breast cancer epithelial cells was then 
used to perform mammosphere assay.
Mammosphere culture
MCF-7 and MDA-MB-231 monolayer cells 
were enzymatically and manually disaggregated to 
obtain single-cell suspension. Single cells were plated 
in ultralow attachment plates (Corning) at a density 
of 500 cells/cm2 in a serum-free Human mammary 
epithelial cell growth medium (HUMEC), supplemented 
with B27, 20 ng/mL human epidermal growth factor 
(EGF), 4 μg/mL heparin, 5 μg/ml insulin, 1 ng/ml 
hydrocortisone, 1 mg/ml penicillin-streptomycin and 
0,25 μg/ml amphotericin B (Life Technologies). Growth 
factors and treatments (leptin, Life Technologies; AG490 
Sigma; PD98059/LY294002 Calbiochem) were added 
to the mammosphere cultures every 3 days. After 7 days 
mammospheres > 50 μm (primary mammospheres-M1) 
were counted using a microscope (x40 magnification), 
collected, enzymatically dissociated, plated at the same 
seeding density used in the primary generation to obtain 
secondary mammospheres-M2. Mammosphere cultures 
from metastatic breast patient-derived cells was assessed 
as described [49]. Mammospheres forming efficiency 
(MFE) was calculated as number of mammospheres per 
well/number of cells seeded per well and reported as fold 
versus control.
Flow cytometry
Mammospheres were dispersed to obtain single-cell 
suspension. Cells were washed in PBS with 2,5% BSA and 
stained with FITC anti-human CD44 and PE anti-human 
CD24 (BD Biosciences), according to the supplier’s 
protocol. Flow cytometric analysis was performed on 
a FACScan and acquisition was performed with WinDI 
software (Becton Dickinson).
Reverse transcription and real-time reverse 
transcriptase PCR assays
PPARγ/OB/FAP/36B4 mRNA expression was 
evaluated by the RT–PCR method as described [50]. Real-
time RT-PCR was assessed using SYBR Green Universal 
PCR Master Mix (Biorad). Each sample was normalized 
on its GAPDH mRNA content. Relative gene expression 
levels were calculated as previously described [50]. 
Primers in Supplementary Table S1.
Immunoblot analysis
Protein extracts were subjected to SDS-PAGE as 
described [50]. Immunoblots show a single representative 
of 3 separate experiments.
Transmigration assays
Mammosphere derived MCF-7 cells were placed 
in the upper compartments of Boyden chamber (8-μm 
membranes/Corning Costar) and transmigration assay was 
performed as described [9].
Lentiviral transfection
We established stable OBR sh MCF-7 cell line using 
the lentiviral expression system (GeneCopoeia; lentiviral 
plasmid sh-clone #HSH010584). 48 h after transfection 
with packaging plasmids and pLentiviral plasmids of 
target gene in HEK293 cells, supernatants containing 
lentiviral particles were filtered (0.45 μm PES), mixed 
with polybrene (8 μg/ml) and used to infect MCF-7 cells. 
24 h after infection, cells were selected with 2 μg/mL 
puromycin overtime to eliminate un-infected cells. OBR 
mRNA expression in stable MCF-7 clones was evaluated 
by real-time RT-PCR.
Microarray and data analysis
Microarray analyses were carried out on total RNA 
from MCF-7-M2 mammosphere-derived cells treated 
with CAF-CM, Adipocyte-CM or Leptin by pooling 
equal amounts of nucleic acids extracted from three 
independent cell cultures. Gene expression profiling was 
performed in triplicate using 500ng of each RNA pool as 
described [51], cRNAs were hybridized for 18 h at 55°C 
on Illumina HumanHT-12 v4.0 BeadChips (Illumina Inc.) 
and scanned with an Illumina iSCAN. Data analyses were 
performed with GenomeStudio software version 2011.1 
(Illumina Inc.). Data were normalized with the quantile 
algorithm and genes were considered if the detection p-
value was < 0.01. Statistical significance was calculated 
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with the Illumina DiffScore, a proprietary algorithm 
that uses the bead standard deviation to build an error 
model. Transcripts showing a DiffScore ≤− 30 and ≥ 30, 
corresponding to a p-value of 0.001 and significant fold 
change in treated vs untreated ≥ 1.5 were considered. 
Venn diagram was generated using Venny 2.0 software. 
Heat-maps were generated with the Multiexperiment 
Viewer 4.9 software after performing one way hierarchical 
clustering of transcripts with the average linkage method 
and Euclidian distance.
Raw microarray data have been deposited, in a 
format complying with the Minimum Information About 
a Microarray Gene Experiment (MIAME) guidelines of 
the Microarray Gene Expression Data Society (MGED), 
in the EBI ArrayExpress database (http://www.ebi.ac.uk/ 
arrayexpress) with Accession Number: E-MTAB-3641.
Total RNA from 8 different metastatic breast 
cancer samples was extracted using the RNeasy Plus 
Mini Kit (QIAGEN). The Exon Gene Array ST1 platform 
(Affimetrix) was used to assess gene expression. Data 
obtained were analysed using Bioconductor R Software. 
The mean of log2 gene expression values was calculated 
across all 8 patient derived samples for each individual 
gene.
Construction of RNA-seq database
RNA-seq data was obtained from the TCGA 
depository. We transferred the pre-processed level 3 data 
generated by the Illumina HiSeq 2000 RNA Sequencing 
Version 2 platform. Expression levels for these samples 
were computed using a combination of MapSplice and 
RSEM. Individual patient files were merged into a single 
database using the plyr R package [52].
Statistical analyses
Each datum point represents the mean ± s.d. of three 
different experiments. Data were analyzed by Student’s 
t test using the GraphPad Prism 4 software. P < 0.05 was 
considered as statistically significant. Pearson correlation 
coefficient (r) was used to measure the correlation 
between OBR or Heat Shock Protein 90 (HSP90) 
gene expression of 8 metastatic breast cancer samples 
and mean MFE; a 2-tailed p ≤ 0.05 was considered 
statistically significant.
Kaplan-Meier analysis was performed as described 
[53]. Kaplan-Meier survival graph, and hazard ratio 
with 95% confidence intervals and logrank P value 
were calculated and plotted in R using Bioconductor 
packages.
CONFLICTS OF INTEREST
The authors declare they have no conflict of interest.
GRANT SUPPORT
This work was supported by PRIN-MIUR 
(Programmi di Ricerca Scientifica di Rilevante Interesse 
Nazionale-Ministero dell’Istruzione dell’Università 
della Ricerca) 2010–2011 and Associazione Italiana per 
la Ricerca sul Cancro (AIRC) grants: IG-11595 and IG-
13176. European Commission/FSE/Regione Calabria to 
FC and SP and Lilli Funaro foundation to SP.
REFERENCES
1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. 
CA Cancer J Clin. 2010; 60:277–300.
2. Visvader JE, Lindeman GJ. Cancer stem cells in solid 
tumours: accumulating evidence and unresolved questions. 
Nat Rev Cancer. 2008; 8:755–768.
3. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, 
Jones DL, Visvader J, Weissman IL, Wahl GM. Cancer 
stem cells—perspectives on current status and future direc-
tions: AACR Workshop on cancer stem cells. Cancer Res. 
2006; 66:9339–9344.
4. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu 
MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, 
Wong H, Rosen J, Chang JC. Intrinsic resistance of tumori-
genic breast cancer cells to chemotherapy. J Natl Cancer 
Inst. 2008; 100:672–679.
5. Phillips TM, McBride WH, Pajonk F. The response of 
CD24(-/low)/CD44+ breast cancer-initiating cells to radia-
tion. J Natl Cancer Inst. 2006; 98:1777–1785.
6. Kakarala M, Wicha MS. Implications of the cancer stem-
cell hypothesis for breast cancer prevention and therapy. 
J Clin Oncol. 2008; 26:2813–2820.
7. Liu S, Dontu G, Wicha MS. Mammary stem cells, self-
renewal pathways, and carcinogenesis. Breast Cancer Res. 
2005; 7:86–95.
8. Korkaya H, Liu S, Wicha MS. Breast cancer stem cells, 
cytokine networks, and the tumor microenvironment. J Clin 
Invest. 2011; 121:3804–3809.
9. Barone I, Catalano S, Gelsomino L, Marsico S, Giordano C, 
Panza S, Bonofiglio D, Bossi G, Covington KR, Fuqua SA, 
Andò S. Leptin mediates tumor-stromal interactions that 
promote the invasive growth of breast cancer cells. Cancer 
Res. 2012; 72:1416–1427.
10. Cirillo D, Rachiglio AM, la Montagna R, Giordano A, 
Normanno N. Leptin signaling in breast cancer: an over-
view. J Cell Biochem. 2008; 105:956–964.
11. Ishikawa M, Kitayama J, Nagawa H. Enhanced expression 
of leptin and leptin receptor (OB-R) in human breast cancer. 
Clin Cancer Res. 2004; 10:4325–4331.
12. Miyoshi Y, Funahashi T, Tanaka S, Taguchi T, Tamaki Y, 
Shimomura I, Noguchi S. High expression of leptin receptor 
mRNA in breast cancer tissue predicts poor prognosis for 
Oncotarget13www.impactjournals.com/oncotarget
patients with high, but not low, serum leptin levels. Int J 
Cancer. 2006; 118:1414–1419.
13. Andò S, Barone I, Giordano C, Bonofiglio D, Catalano S. 
The Multifaceted Mechanism of Leptin Signaling within 
Tumor Microenvironment in Driving Breast Cancer Growth 
and Progression. Front Oncol. 2014; 4:340.
14. Andò S, Catalano S. The multifactorial role of leptin in 
driving the breast cancer microenvironment. Nat Rev 
Endocrinol. 2011; 8:263–275.
15. Saxena NK, Sharma D. Multifaceted leptin network: the 
molecular connection between obesity and breast cancer. J 
Mammary Gland Biol Neoplasia. 2013; 18:309–320.
16. Catalano S, Marsico S, Giordano C, Mauro L, Rizza P, 
Panno ML, Andò S. Leptin enhances, via AP-1, expression 
of aromatase in the MCF-7 cell line. J Biol Chem. 2003; 
278:28668–28676.
17. Catalano S, Mauro L, Marsico S, Giordano C, Rizza P, 
Rago V, Montanaro D, Maggiolini M, Panno ML, Andò 
S. Leptin induces, via ERK1/ERK2 signal, functional acti-
vation of estrogen receptor alpha in MCF-7 cells. J Biol 
Chem. 2004; 279:19908–19915.
18. Fiorio E, Mercanti A, Terrasi M, Micciolo R, Remo A, 
Auriemma A, Molino A, Parolin V, Di Stefano B, Bonetti 
F, Giordano A, Cetto GL, Surmacz E. Leptin/HER2 cross-
talk in breast cancer: in vitro study and preliminary in vivo 
analysis. BMC Cancer. 2008; 8:305.
19. Soma D, Kitayama J, Yamashita H, Miyato H, Ishikawa 
M, Nagawa H. Leptin augments proliferation of breast can-
cer cells via transactivation of HER2. J Surg Res. 2008; 
149:9–14.
20. Giordano C, Vizza D, Panza S, Barone I, Bonofiglio D, 
Lanzino M, Sisci D, De Amicis F, Fuqua SA, Catalano S, 
Andò S. Leptin increases HER2 protein levels through a 
STAT3-mediated up-regulation of Hsp90 in breast cancer 
cells. Mol Oncol. 2013; 7:379–391.
21. Saxena NK, Taliaferro-Smith L, Knight BB, Merlin D, 
Anania FA, O’Regan RM, Sharma D. Bidirectional cross-
talk between leptin and insulin-like growth factor-I signal-
ing promotes invasion and migration of breast cancer cells 
via transactivation of epidermal growth factor receptor. 
Cancer Res. 2008; 68:9712–9722.
22. Newman G, Gonzalez-Perez RR. Leptin-cytokine crosstalk 
in breast cancer. Mol Cell Endocrinol. 2014; 382:570–582.
23. Feldman DE, Chen C, Punj V, Tsukamoto H, Machida K. 
Pluripotency factor-mediated expression of the leptin recep-
tor (OB-R) links obesity to oncogenesis through tumor-
initiating stem cells. Proc Natl Acad Sci U S A. 2012; 
109:829–834.
24. Zheng Q, Dunlap SM, Zhu J, Downs-Kelly E, Rich J, 
Hursting SD, Berger NA, Reizes O. Leptin deficiency sup-
presses MMTV-Wnt-1 mammary tumor growth in obese 
mice and abrogates tumor initiating cell survival. Endocr 
Relat Cancer. 2011; 18:491–503.
25. Zheng Q, Banaszak L, Fracci S, Basali D, Dunlap SM, 
Hursting SD, Rich JN, Hjlemeland AB, Vasanji A, Berger 
NA, Lathia JD, Reizes O. Leptin receptor maintains cancer 
stem-like properties in triple negative breast cancer cells. 
Endocr Relat Cancer. 2013; 20:797–808.
26. Chang CC, Wu MJ, Yang JY, Camarillo IG, Chang CJ. 
Leptin-STAT3-G9a Signaling Promotes Obesity-Mediated 
Breast Cancer Progression. Cancer Res. 2015; .
27. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke 
MF, Kawamura MJ, Wicha MS. In vitro propagation and 
transcriptional profiling of human mammary stem/progeni-
tor cells. Genes Dev. 2003; 17:1253–1270.
28. Catalano S, Leggio A, Barone I, De Marco R, Gelsomino L, 
Campana A, Malivindi R, Panza S, Giordano C, Liguori A, 
Bonofiglio D, Liguori A, Andò S. A novel leptin antagonist 
peptide inhibits breast cancer growth in vitro and in vivo. 
J Cell Mol Med. 2015; 19:1122–1132.
29. Isolani ME, Conte M, Deri P, Batistoni R. Stem cell protec-
tion mechanisms in planarians: the role of some heat shock 
genes. Int J Dev Biol. 2012; 56:127–133.
30. May CD, Sphyris N, Evans KW, Werden SJ, Guo W, Mani 
SA. Epithelial-mesenchymal transition and cancer stem 
cells: a dangerously dynamic duo in breast cancer progres-
sion. Breast Cancer Res. 2011; 13:202.
31. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, 
Regev A, Weinberg RA. An embryonic stem cell-like gene 
expression signature in poorly differentiated aggressive 
human tumors. Nat Genet. 2008; 40:499–507.
32. Honeth G, Bendahl PO, Ringner M, Saal LH, Gruvberger-
Saal SK, Lovgren K, Grabau D, Ferno M, Borg A, Hegardt 
C. The CD44+/CD24- phenotype is enriched in basal-like 
breast tumors. Breast Cancer Res. 2008; 10:R53.
33. Park SY, Lee HE, Li H, Shipitsin M, Gelman R, Polyak 
K. Heterogeneity for stem cell-related markers according 
to tumor subtype and histologic stage in breast cancer. Clin 
Cancer Res. 2010; 16:876–887.
34. Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, 
Moreno-Bueno G, Palacios J. Epithelial-mesenchymal tran-
sition in breast cancer relates to the basal-like phenotype. 
Cancer Res. 2008; 68:989–997.
35. Pattabiraman DR, Weinberg RA. Tackling the cancer 
stem cells - what challenges do they pose?. Nat Rev Drug 
Discov. 2014; 13:497–512.
36. Beck B, Blanpain C. Unravelling cancer stem cell potential. 
Nat Rev Cancer. 2013; 13:727–738.
37. Siddique HR, Saleem M. Role of BMI1, a stem cell 
factor, in cancer recurrence and chemoresistance: 
preclinical and clinical evidences. Stem Cells. 2012; 
30:372–378.
38. Trosko JE, Chang CC, Upham BL, Tai MH. Ignored hall-
marks of carcinogenesis: stem cells and cell-cell communi-
cation. Ann N Y Acad Sci. 2004; 1028:192–201.
Oncotarget14www.impactjournals.com/oncotarget
39. Zhou BO, Yue R, Murphy MM, 1 Peyer JG, Morrison S J. 
Leptin-Receptor-Expressing Mesenchymal Stromal Cells 
Represent the Main Source of Bone Formed by Adult Bone 
Marrow. Cell Stem Cell. 2014; 15:154–168.
40. Hu X, Wu R, Jiang Z, Wang L, Chen P, Zhang L, Yang L, 
Wu Y, Chen H, Chen H, Xu Y, Zhou Y, Huang X, Webster 
KA, Yu H, Wang J. Leptin signaling is required for aug-
mented therapeutic properties of mesenchymal stem cells 
conferred by hypoxia preconditioning. Stem Cells. 2014; 
10:2702–13.
41. Chen P, Wu R, Zhu W, Jiang Z, Xu Y, Chen H, Zhang 
Z, Chen H, Zhang L, Yu H, Wang J, Hu X. Hypoxia 
Preconditioned Mesenchymal Stem Cells Prevent Cardiac 
Fibroblast Activation and Collagen Production via Leptin. 
PloS ONE. 2014; 9:e103587.
42. Zhou J, Wulfkuhle J, Zhang H, Gu P, Yang Y, Deng 
J, Margolick JB, Liotta LA, Petricoin E 3rd, Zhang Y. 
Activation of the PTEN/mTOR/STAT3 pathway in breast 
cancer stem-like cells is required for viability and mainte-
nance. Proc Natl Acad Sci U S A. 2007; 104:16158–16163.
43. Pratt MA, Tibbo E, Robertson SJ, Jansson D, Hurst 
K, Perez-Iratxeta C, Lau R, Niu MY. The canonical 
NF-kappaB pathway is required for formation of luminal 
mammary neoplasias and is activated in the mammary pro-
genitor population. Oncogene. 2009; 28:2710–2722.
44. Guo S, Gonzalez-Perez RR. Notch, IL-1 and leptin crosstalk 
outcome (NILCO) is critical for leptin-induced prolifera-
tion, migration and VEGF/VEGFR-2 expression in breast 
cancer. PLoS One. 2011; 6:e21467.
45. Knight BB, Oprea-Ilies GM, Nagalingam A, Yang L, Cohen 
C, Saxena NK, Sharma D. Survivin upregulation, dependent 
on leptin-EGFR-Notch1 axis, is essential for leptin-induced 
migration of breast carcinoma cells. Endocr Relat Cancer. 
2011; 18:413–428.
46. Guo S, Liu M, Wang G, Torroella-Kouri M, Gonzalez-
Perez RR. Oncogenic role and therapeutic target of leptin 
signaling in breast cancer and cancer stem cells. Biochim 
Biophys Acta. 2012; 1825:207–222.
47. Farnie G, Clarke RB, Spence K, Pinnock N, Brennan K, 
Anderson NG, Bundred NJ. Novel cell culture technique 
for primary ductal carcinoma in situ: role of Notch and epi-
dermal growth factor receptor signaling pathways. J Natl 
Cancer Inst. 2007; 99:616–627.
48. Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, 
Ronzoni S, Bernard L, Viale G, Pelicci PG, Di Fiore PP. 
Biological and molecular heterogeneity of breast cancers 
correlates with their cancer stem cell content. Cell. 2010; 
140:62–73.
49. Shaw FL, Harrison H, Spence K, Ablett MP, Simoes BM, 
Farnie G, Clarke RB. A detailed mammosphere assay pro-
tocol for the quantification of breast stem cell activity. J 
Mammary Gland Biol Neoplasia. 2012; 17:111–117.
50. Catalano S, Malivindi R, Giordano C, Gu G, Panza S, 
Bonofiglio D, Lanzino M, Sisci D, Panno ML, Andò S. 
Farnesoid X receptor, through the binding with steroido-
genic factor 1-responsive element, inhibits aromatase 
expression in tumor Leydig cells. J Biol Chem. 2010; 
285:5581–5593.
51. Nassa G, Tarallo R, Giurato G, De Filippo MR, Ravo M, 
Rizzo F, Stellato C, Ambrosino C, Baumann M, Lietzen 
N, Nyman TA, Weisz A. Post-transcriptional regulation of 
human breast cancer cell proteome by unliganded estrogen 
receptor beta via microRNAs. Mol Cell Proteomics. 2014; 
13:1076–1090.
52.  Wickham . The Split-Apply-Combine Strategy for Data 
Analysis. J Stat Softw. 2011; 40:1–29.
53. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, 
Li Q, Szallasi Z. An online survival analysis tool to rapidly 
assess the effect of 22,277 genes on breast cancer prognosis 
using microarray data of 1,809 patients. Breast Cancer Res 
Treat. 2010; 123:725–731.
